P. Webborn

发表

Chapter 10 – Metabolism and pharmacokinetic optimization strategies in drug discovery

P. Ballard, K. Bui, P. Brassil, 2013 .

Induced Correlations in the Use of Unbound/Intrinsic Pharmacokinetic Parameters in Quantitative Structure-Pharmacokinetic Relationships with Lipophilicity

David W. Salt, Andrew M. Davis, A. Davis, 2000 .

Development of Pyrazolopyrimidine Anti-Wolbachia Agents for the Treatment of Filariasis

M. Wenlock, G. Nixon, N. Berry, 2021, ACS medicinal chemistry letters.

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.

P. Leeson, B. Springthorpe, P. Barton, 2007, Bioorganic & medicinal chemistry letters.

Design of Helicobacter pylori glutamate racemase inhibitors as selective antibacterial agents: a novel pro-drug approach to increase exposure.

G. Basarab, P. Webborn, P. Hill, 2008, Bioorganic & medicinal chemistry letters.

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.

B. Springthorpe, R. Riley, H. Beaton, 2012, Bioorganic & medicinal chemistry letters.

Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.

Matthew W D Perry, Emma Roe, Robert J Riley, 2012, Bioorganic & medicinal chemistry letters.

Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists.

Martin Braddock, Keith Bowers, Richard Weaver, 2003, Bioorganic & medicinal chemistry letters.

Mass spectrometry imaging in drug development.

Peter J H Webborn, Per E Andrén, Theodosia Vallianatou, 2015, Analytical chemistry.

AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis

J. Archer, A. Hoerauf, J. Hemingway, 2019, Proceedings of the National Academy of Sciences.

The right compound in the right assay at the right time: an integrated discovery DMPK strategy

Peter Ballard, Patrick Brassil, Khanh H Bui, 2012, Drug metabolism reviews.

Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes

Peter J H Webborn, Robert J Riley, R. Riley, 2008, Drug Metabolism and Disposition.

Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

Ken Grime, R. Riley, Robert J. Riley, 2007, Drug Metabolism and Disposition.

Drug-phospholipid interactions. 2. Predicting the sites of drug distribution using n-octanol/water and membrane/water distribution coefficients.

A. Davis, P. Webborn, P. Barton, 1997, Journal of pharmaceutical sciences.

Future directions of imaging MS in pharmaceutical R&D.

Peter J H Webborn, Richard J A Goodwin, R. Goodwin, 2015, Bioanalysis.

Mass spectrometry imaging of cassette-dosed drugs for higher throughput pharmacokinetic and biodistribution analysis.

Peter J H Webborn, Nicole Strittmatter, Malcolm R Clench, 2014, Analytical chemistry.

Mapping drug distribution in brain tissue using liquid extraction surface analysis mass spectrometry imaging.

Peter J H Webborn, Malcolm R Clench, Richard J A Goodwin, 2015, Analytical chemistry.

Spatial Quantitation of Drugs in tissues using Liquid Extraction Surface Analysis Mass Spectrometry Imaging

Malcolm R. Clench, Richard J. A. Goodwin, Nicole Strittmatter, 2016, Scientific Reports.

Robust assessment of statistical significance in the use of unbound/intrinsic pharmacokinetic parameters in quantitative structure-pharmacokinetic relationships with lipophilicity.

A M Davis, A. Davis, D. Salt, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.

Peter J H Webborn, Robert J Riley, R. Riley, 2009, Molecular pharmaceutics.

In vitro–in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects

R J Riley, R. Riley, P. Webborn, 2007, Xenobiotica; the fate of foreign compounds in biological systems.

Actives from MMV Open Access Boxes? A suggested way forward

J. Burrows, P. Webborn, P. Willis, 2021, PLoS pathogens.

Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors.

Martin Braddock, Mark Furber, Keith Bowers, 2007, Journal of medicinal chemistry.

Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.

J. Breed, V. Oza, P. Lyne, 2010, Bioorganic & medicinal chemistry letters.

Hepatic Uptake in the Dog: Comparison of Uptake in Hepatocytes and Human Embryonic Kidney Cells Expressing Dog Organic Anion-Transporting Polypeptide 1B4

K. Maeda, H. Kusuhara, Y. Sugiyama, 2011, Drug Metabolism and Disposition.

Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes

R. Riley, P. Webborn, K. Grime, 2008, Drug Metabolism and Disposition.

In vitro–in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects

P. Webborn, A. J. Parker, Rebecca Denton, 2007, Xenobiotica; the fate of foreign compounds in biological systems.

AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis

Edward W. Tate, J. Archer, A. Hoerauf, 2019, Proceedings of the National Academy of Sciences.

The role of pharmacokinetic studies in drug discovery: where are we now, how did we get here and where are we going?

P. Webborn, 2014, Future medicinal chemistry.